Invigor Medical states it is licensed in all 50 states and claims more than 35,000 customers with a 4.7 average rating. Its weight-loss range has four entries — and half of them are for something that does not have an evidence base.
Micro-Dosing Is Not a Protocol
Invigor lists “GLP-1 Micro-Dosing” and “GLP-1 + GIP Micro-Dosing” as distinct products. There is no established microdosing protocol for semaglutide or tirzepatide.
These medications were studied at specific doses with defined escalation schedules, and the weight-loss results everyone cites come from those regimens. A dose below the studied range is not a gentler version of a proven treatment — it is a dose nobody has tested for this purpose.
The word does a lot of quiet work. “Micro-dosing” borrows credibility from contexts where it means something specific, and implies a considered clinical strategy: fewer side effects, same benefit, lower cost. None of that has been demonstrated here. What is plausible is that a lower dose produces fewer gastrointestinal effects — and proportionally less weight loss, which is not a discovery.
There is a legitimate clinical practice nearby, which is worth distinguishing. Clinicians do hold patients at a lower dose when side effects are intolerable, or titrate more slowly than the label schedule. That is individualised dose management by a prescriber who knows you. It is not the same as marketing a sub-therapeutic dose as its own product tier before anyone has assessed you.
This is the second provider in this round selling micro-dosing as a product line — our Belle review flags the same thing — which suggests a category trend rather than one company’s idea. Treat it as a marketing tier, and ask what actual dose in milligrams you would be prescribed.
It Never Names the Medication
The products are called “GLP-1 Treatment” and “GLP-1 + GIP Treatment”. Nowhere on the page we checked does the site say semaglutide or tirzepatide, or state whether the products are compounded or brand-name.
“GLP-1 + GIP” describes tirzepatide’s dual mechanism, so that is almost certainly what it means — but a patient should not have to infer the molecule they are being prescribed from a mechanism description. The compounded-or-approved question is the single most consequential fact about a GLP-1 purchase in 2026, given the shortage pathway closed when the FDA resolved the tirzepatide shortage in October 2024 and the semaglutide shortage on 21 February 2025. Our compounded versus brand-name guide covers why it matters.
No pricing is published either — not for medication, consultations or membership.
What It Does Have
50-state licensing is a genuine advantage. Telehealth prescribing is licensed state by state, and a great many services on this site serve a partial map or decline to say — our Coby Health review credits that company simply for naming its four exclusions. Nationwide coverage means the answer is yes wherever you are.
A claimed 35,000+ customers and 4.7 average from 1,000+ reviews suggests an established operation rather than a new arrival. We could not verify those figures at source and they are self-reported, so treat them as claims — but scale of that kind is not typically fabricated wholesale, and it does indicate the service functions.
Provider Facts
| Medications offered | Listed as GLP-1 Treatment, GLP-1 + GIP Treatment, GLP-1 Micro-Dosing and GLP-1 + GIP Micro-Dosing. Active ingredients are not named |
|---|---|
| Brand-name or compounded | Not stated - the site does not say whether products are compounded or brand-name |
| Consultation process | Online; format, length and cost not published |
| Eligibility | Not published - no BMI threshold stated |
| Provider involvement | Not published |
| Lab requirements | Not published |
| Pharmacy fulfillment | Not published |
| Shipping frequency | Not published |
| Support services | Not published |
| Membership fees | Not published |
| Medication fees | Not published |
| Cancellation policy | Not published |
| Refund policy | Not published |
| Insurance | Not published |
| HSA/FSA | Not published |
| Availability | Stated as licensed in all 50 states |
Pros and Cons
Pros
- Licensed in all 50 states — no coverage gap
- Claimed 35,000+ customers suggests an established operation
- Claimed 4.7 average across 1,000+ reviews
- Both single-agonist and dual GLP-1/GIP options offered
Cons
- Sells micro-dosing, which has no established protocol
- Never names the active medication
- Does not say whether products are compounded or brand-name
- No pricing published of any kind
- No eligibility, labs, pharmacy or refund information
- Customer and rating figures are self-reported and unverified
Who It May Be Best For
Potentially suitable if you live in a state most GLP-1 telehealth will not serve and you need the widest possible licensing footprint.
Ask before anything else: which molecule, compounded or brand-name, what dose in milligrams, and what the total monthly cost is. Four questions the site should answer and does not.
Avoid the micro-dosing tiers unless a prescriber who has assessed you specifically recommends a lower dose for a reason they can explain — which is a clinical decision, not a product you should be selecting from a menu.
Alternatives
Zappy Health names every medication and publishes every price. Amazon One Medical is brand-name only with insurance accepted. Our best online GLP-1 providers page ranks the field.
Limitations of This Review
Based on Invigor’s homepage at tryinvigor.com checked on 8 August 2026, after invigormedical.com redirected there and a dedicated weight-loss URL returned 404. Detailed medication and pricing information appears to sit on individual treatment pages we did not reach, so figures may exist that we did not see — everything marked not published means we could not find it. The customer count and rating are the company’s own claims and were not verified. Statements about GLP-1 dosing and the absence of a microdosing protocol reflect published trial regimens rather than any claim by Invigor. Nothing here is medical advice.
Frequently Asked Questions
Is GLP-1 micro-dosing a real treatment?
Not an established one. Semaglutide and tirzepatide were studied at specific escalating doses, and a dose below that range has not been tested for weight loss. A lower dose plausibly causes fewer side effects and proportionally less weight loss.
Is holding a lower dose ever appropriate?
Yes — clinicians routinely slow titration or hold a dose when side effects are intolerable. That is individualised management by someone who has assessed you, which is different from buying a sub-therapeutic tier off a menu.
What medication would I actually get?
The site does not say. “GLP-1 + GIP” describes tirzepatide’s mechanism, but neither the molecule nor whether it is compounded or brand-name is stated. Ask before paying.
Which states does it serve?
It states licensing in all 50 states, which is broader than most of this category.
Verdict
2.9 / 5 — pricing unverified
Nationwide licensing and apparent scale are real advantages. Half the weight-loss range is a dose tier with no evidence behind it, and the site will not tell you what drug you are buying or what it costs.
The point worth carrying beyond this provider: “micro-dosing” is appearing across this category as a product tier, and it sounds like a considered clinical strategy. It is a dose below the range these drugs were tested at. If a lower dose is right for you, that is a decision a prescriber makes after assessing you — not an option you pick at checkout.
Medical Disclaimer & Review Date
This review is general consumer information, not medical advice. GLP-1 medications are prescription drugs with serious contraindications, and whether any treatment is appropriate for you is a decision only a licensed healthcare provider who knows your medical history can make. Nothing here should be used to start, stop, or change a medication.
Details in this review come from Invigor Medical's own published materials as of the date below. Pricing, medication availability, state coverage, and policies in this category change frequently — verify current terms directly with the provider before purchasing.
Date reviewed: August 8, 2026